Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2025 | $30.00 | Hold | Stifel |
| 11/22/2024 | $45.00 | Outperform | Evercore ISI |
| 3/7/2024 | $48.00 | Overweight | Piper Sandler |
| 5/1/2023 | Buy | Truist | |
| 8/25/2022 | $5.00 | Neutral → Sell | Goldman |
| 4/13/2022 | $31.00 | Outperform | RBC Capital Mkts |
| 2/14/2022 | $33.00 → $32.00 | Overweight | JP Morgan |
| 1/28/2022 | $11.00 | Neutral | Goldman |
Stifel initiated coverage of Edgewise Therapeutics with a rating of Hold and set a new price target of $30.00
Evercore ISI initiated coverage of Edgewise Therapeutics with a rating of Outperform and set a new price target of $45.00
Piper Sandler initiated coverage of Edgewise Therapeutics with a rating of Overweight and set a new price target of $48.00
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
SCHEDULE 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)
144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)
144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- Robert Blaustein, M.D., Ph.D. appointed as Chief Development Officer (CDO) - - Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the Company's focus on late-stage clinical development. These changes include the addition of Robert Blaustein, M.D., Ph.D., joining the Company as Chief Development Officer and the promotion of Behrad Derakhshan, Ph.D. from Chief Business Officer to Chief Operating Officer. This press release features multimedia. View the full release here: https:
- Advancing robust clinical pipeline of novel therapeutics for serious muscular dystrophies and cardiac conditions - - Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief Executive Officer, Kevin Koch, Ph.D., will present these updates today at the Annual J.P. Morgan Healthcare Conference. "We were pleased with our progress in 2024 as we advanced our drug pipeline and have great momentum heading into 2025. With positive
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 pm PT (4:30 pm ET). The discussion will include updates on its cardiovascular and muscular dystrophy programs and 2025 key milestones. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the
SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
SC 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)
– Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed – – Management hosting webcast to discuss findings on September 12 at 8:30 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today pos
– EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – – EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation to 15 mg daily for all patients – – Management hosting webcast to discuss findings on June 21 at 9:00 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month
- Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022. Edgewise ARCH Interi
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. "With over 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene to our Board," said Kevin Koch, Ph.D., President and Chief Executive Officer. "Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful to count her as a valued advisor as we contin
– President and Chief Medical Officer (CMO) of BridgeBio Pharma and Former CMO of MyoKardia brings strong cardiovascular expertise to Edgewise – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox brings considerable expertise in clinical development and regulatory strategy to Edgewise, serving currently as President and CMO at BridgeBio Pharma, and previously as CMO at MyoKardia, where he was one of the inventors of Camzyos
– Former Chief Medical Officer of MyoKardia and Renovacor to lead cardiovascular development at Edgewise – Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Marc Semigran, M.D., as Chief Development Officer. Dr. Semigran brings considerable clinical development and translational medicine experience to Edgewise, having most recently served as Chief Medical Officer (CMO) at Renovacor through its acquisition by Rocket Pharmaceuticals, Inc., and previously served as CMO and Senior Vice President o